Skip to Content

Join the 'Osteolytic Bone Lesions of Multiple Myeloma' group to help and get support from people like you.

Osteolytic Bone Lesions of Multiple Myeloma News

Related terms: Multiple Myeloma, Osteolytic Bone Lesions

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who received a standard drug duo alone. And over 13.5 months, the daratumumab combination cut patients' risk of dying or seeing their cancer progress by 63 percent, the study found. Researchers called the results "unprecedented" for patients like these. All had relapsed or refractory myeloma – which means the cancer had either come back or failed to respond to the previous treatment. "It is very likely that (this regimen) will be rapidly adopted by practicing physicians," said lead researcher Dr. Meletios ... Read more

Related support groups: Dexamethasone, Multiple Myeloma, Revlimid, Decadron, TobraDex, Ciprodex, Maxitrol, Osteolytic Bone Lesions of Multiple Myeloma, Ozurdex, Lenalidomide, Decadron Tablets, Dexamethasone/Tobramycin, Tobradex ST, Dexamethasone/Neomycin/Polymyxin B, Maxidex, Poly-Dex, Decadron Dose Pack, Dexone, Neo-Poly-Dex, Adrenocot LA

Superior Results for Myeloma Drug That's Added Earlier in Treatment

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – A recently approved immunotherapy drug for a blood cancer called multiple myeloma can provide even better benefits if patients receive it earlier in their treatment, new clinical trial results show. Darzalex (daratumumab) reduced patients' risk of cancer progression by 70 percent when added to a standard two-drug regimen for people with recurring myeloma, said lead researcher Dr. Antonio Palumbo. He is chief of the myeloma unit at the University of Torino department of oncology in Italy. The new drug essentially doubled the response that doctors expect from the standard regimen of bortezomib (another immunotherapy drug) and dexamethasone (a steroid drug). About 19 percent of patients given Darzalex had their cancer go into full remission, compared with just 9 percent of those taking the standard treatment, researchers found. "Very good" response rates doubled to ... Read more

Related support groups: Multiple Myeloma, Osteolytic Bone Lesions of Multiple Myeloma, Darzalex, Daratumumab

Exercise May Cut Risk of 13 Cancers, Study Suggests

Posted 16 May 2016 by Drugs.com

MONDAY, May 16, 2016 – Exercise may significantly reduce your risk for many types of cancer, including some of the most lethal forms of the disease, a large review suggests. Working out for even a couple of hours a week appears to shrink the risk of breast, colon and lung cancer, said researchers who looked at 1.4 million adults. "Those are three of the four major cancers that affect Americans today," said Marilie Gammon. She is a professor of epidemiology with the University of North Carolina at Chapel Hill Gillings School of Public Health. And fitness buffs, take heart – your cancer risk appears to continue to decline as you rack up hours of physical activity, with no apparent upper plateau, said study lead author Steven Moore, an investigator with the U.S. National Cancer Institute. "The more activity, the more the benefit," Moore said. "As people did more, their risk continued to ... Read more

Related support groups: Cancer, Breast Cancer, Leukemia, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Endometrial Cancer, Small Cell Lung Cancer, Acute Myeloid Leukemia, Bladder Cancer, Stomach Cancer, Breast Cancer, Prevention, Head and Neck Cancer, Acute Lymphoblastic Leukemia, Gastric Cancer, Osteolytic Bone Lesions of Multiple Myeloma, Acute Myeloblastic Leukemia, Urinary Tract Cancer

Experimental Drug for Blood Cancer Shows Promise

Posted 26 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 26, 2015 – An experimental immune-boosting drug shows promise in fighting the blood cancer multiple myeloma, researchers report. Preliminary testing of the drug daratumumab included 72 multiple myeloma patients who had previously received other types of treatment. Their disease had relapsed and no longer responded to treatment. The patients received lower or higher doses of the drug for up to two years. Of the 42 patients who received a higher dose, 36 percent had at least partial remission, including two with complete remission, researchers report. In this group, the disease was held in check for a median of 5.6 months. The researchers also found that two-thirds of patients who benefited from the drug had no advance of their cancer for at least 12 months. Results of the combined phase 1 and 2 study strongly support testing the drug in a larger group of patients, the ... Read more

Related support groups: Fatigue, Fever, Pneumonia, Cough and Nasal Congestion, Multiple Myeloma, Velcade, Osteolytic Bone Lesions of Multiple Myeloma, Bortezomib, Carfilzomib, Kyprolis

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma

Related Drug Support Groups

Reclast, Zometa, zoledronic acid, Aclasta, pamidronate, Aredia